CRISPR Therapeutics: Bullish Article Clashes with Cautious Financial Reality

What happened

A Seeking Alpha article published on April 1, 2026, touts CRISPR Therapeutics as at a turning point with accelerating CASGEVY commercial growth and a robust pipeline, rating it Buy with a $64.58 price target. It highlights increasing patient initiations and revenue growth as a near-term path to profitability, while emphasizing pipeline potential in cardiovascular markets. However, the latest DeepValue master report maintains a 'WAIT' rating, critically noting that CRSP is priced for launch proof but not yet an earnings story, with key risks unresolved. The report reveals that CASGEVY-related expenses exceeded revenue share in 2025, driving a widened 4Q25 net loss of $130.6 million despite $54 million revenue, and warns of potential shareholder dilution from $557.2 million remaining ATM capacity. This creates a stark contrast between optimistic projections and the harsh financial realities of ongoing losses and operational bottlenecks.

Implication

The Seeking Alpha article may boost short-term sentiment, but it glosses over the DeepValue report's findings that CASGEVY's collaboration expenses are structurally outpacing revenue, preventing near-term profitability. CRSP's valuation depends on converting first cell collections into infusions, a process lagging in 2025 and indicating persistent operational constraints. Management's reliance on ATM issuance for funding, with $557.2 million capacity remaining, risks diluting shareholders before economics improve. Pipeline advancements, while a long-term tailwind, are secondary to the immediate need for infusion growth and expense normalization. Therefore, prudent investors should wait for concrete quarterly evidence of infusion acceleration and controlled ATM usage before considering an entry.

Thesis delta

The Seeking Alpha article reinforces a bullish narrative but does not alter the fundamental investment thesis from the DeepValue report. No shift is warranted, as the report's 'WAIT' rating remains justified until CRSP demonstrates infusion growth tracking with collections and limited dilution. Investors should ignore the hype and focus on upcoming quarterly prints for confirmation of operational progress.